New drug approval for MET exon 14 skipping mutation

[Miranda_GO2]

"On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Here is the link from the FDA to read more: fda.gov/drugs/drug-approval....

Read more about this in this week's Weekly Breather from GO2. Sign up for the Weekly Breather at this link: secure.go2foundation.org/si...